Report on TROP2 expression across tumors

Stephen V Liu shared a paper by Dan Morgenstern-Kaplan et al, on X:

“Report on TROP2 expression across tumors in The Oncologist. TROP2 high tumors often with co-mutations in TP53 (breast, CRC, panc, HCC), KRAS (panc, CRC), ARID1A and FGFR3 (urothelial), and CTNNB1 (HCC). High expression had a poor prognosis.”

Source: Stephen V Liu/X

Authors: Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris Krause, Jennifer R Ribeiro, Heng Tan, Emmanuel S Antonarakis, Emil Lou, Misako Nagasaka, Sandra Algaze, Heinz-Josef Lenz, Stephen V Liu, Balazs Halmos, Dave S B Hoon, Andreas Seeber, Patrick C Ma, Wafik S El-Deiry, Ari M Vanderwalde, Gilberto Lopes

Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors 

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.